ASCO 2017: Testicular cancer debate summary


August 23, 2017

  • Share this post:

On February 16-18, the 2017 Genitourinary Cancers Symposium took place in Orlando, Florida. A debate was held on February 18 about marker half-life decline as a predictor of response in testicular cancer.

Prof. George Bosl from the Memorial Sloan Kettering Cancer Center reflects on the key points from the debate:

  • Usage of marker half-life decline in clinical practice
  • Marker surge after surgery and effects on measurement
  • Accuracy of marker decline as a predictor for response
  • Marker-free patients
  • Future directions to address controversies

This program is financially supported by Bayer and Janssen Oncology.

Related articles